Marc C. Smaldone, MD, MSHP, FACS

Marc Smaldone, MD, MSHP
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings
Request an Appointment

Clinical Locations

Director, Surgical Quality, Department of Urology

Professor of Urology

 

Treatment Focus

  • Robotic and laparoscopic minimally invasive surgery
  • Continent urinary diversion
  • Salvage and reconstructive Surgery

Key Awards

2023 top doctors
Urology

Treatment Philosophy

I am a urologic oncologist specializing in the surgical management of tumors of the kidney, bladder, prostate, adrenal, testis and other genitourinary organs. As part of the multi-disciplinary Genitourinary Cancer Patient Care Team, I work closely with my colleagues in Medical and Radiation Oncology to develop a comprehensive treatment plan that offers the best chance for cure for each patient.

The mission at the Fox Chase Cancer Center is to deliver world class oncologic care in the most compassionate and respectful way possible. A cancer diagnosis brings fear and uncertainty for patients and their families, and my personal philosophy is to treat patients how I would wish for my family members to be treated. Patient education is essential, and I consider it of utmost importance to take the time necessary for patients to understand and feel comfortable with all possible treatment options to inspire confident decision making.

I have expertise in open, laparoscopic, and robotic surgical techniques, which allows me to tailor a specific treatment plan based on individual patient need and preferences. I have particular expertise in minimally invasive organ preserving and reconstructive techniques to preserve function and quality of life, including nerve-sparing prostatectomy for patients with prostate cancer and partial nephrectomy for patients with kidney cancer. I have experience performing both robotic and open cystectomy for patients with bladder cancer, and prefer to construct continent urinary diversions whenever possible. I have a clinical interest in the surgical management of patients with high risk and advanced disease, and have experience performing retroperitoneal lymph node dissection following chemotherapy in patients with testicular cancer, cytoreductive nephrectomy and thrombectomy for patients with metastatic kidney cancer or tumors extending into the vena cava, and salvage surgery following radiation for patients with bladder or prostate cancer.

Follow on Twitter: @FCUroOnc

Educational Background

  • Fellowship: Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Residency: Urologic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA
  • MS, Health Policy Research, University of Pennsylvania, Philadelphia, PA
  • MD, State University of New York at Stony Brook School of Medicine, Stony Brook, NY

Certifications

  • American Board of Urology

Memberships

  • National Comprehensive Cancer Network (NCCN)
    • Prostate Cancer Early Detection Panel
  • American Urological Association
  • Society of Urologic Oncology

Honors & Awards

  • Main Line Today Top Doctors, 2018-2019

Brian Kredo

  • Bladder Cancer

My name is Brian Kredo and I am 53 years old. I work as a lawyer and live in Bucks County, which is in suburban Philadelphia, with my wife Jodi and my two teenage children.

A few years ago, I noticed some drops of blood at the end of my urine stream. When I went to see my urologist, he ran some tests, and the results came back atypical. He said we’d need to do a biopsy, but he was going on vacation for two weeks, so he wanted to do it when he got back. That felt like too long to wait.

VIEW PATIENT STORY

Bill Doyle

  • Bladder Cancer

Bill Doyle always knew he wanted to be on the radio. As one half of the Deminski & Doyle talk radio show on New Jersey 101.5, life was good for Bill until he was diagnosed with bladder cancer at 52. After surgery and several rounds of chemotherapy, Bill is back on the airwaves, thanks in part to the support of his family and the countless 101.5 listeners who have offered words of support during his cancer journey.

VIEW PATIENT STORY

Research Interests

  • Quality of care
  • Comparative effectiveness
  • Risk assessment
  • Access disparities
  • Surgical outcomes
  • Health services research

Selected Publications

Masic S.,Smaldone M.C., Robotic renal surgery for renal cell carcinoma with inferior vena cava thrombus. Transl Androl Urol. 10(5): 2195-2198, 2021. PMC8185684. https://www.ncbi.nlm.nih.gov/pubmed/34159102.

Smaldone M.C., Tomaszewski J.J., Current controversies in minimally invasive urologic oncology. Transl Androl Urol. 10(5): 2149-2150, 2021.PMC8185655 (available at http://dx.doi.org/10.21037/tau-21-258). https://www.ncbi.nlm.nih.gov/pubmed/34159096.

Correa AF, Handorf E, Joshi SS, Geynisman DM, Kutikov A, Chen DY, Uzzo RG, Viterbo R, Greenberg RE, Smaldone MC. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol, 199(5):1238-44, 2018. PubMed

Goel N, Manstein SM, Ward WH, DeMora L, Smaldone MC, Farma JM, Uzzo RG, Esnaola NF. Does the Surgical Apgar Score predict serious complications after elective major cancer surgery? Journal of Surgical Research, 231:242-7, 2018. 

Smaldone, M.C., Corcoran, A.T., Hayn M.H., Konety, B.R., Hrebinko Jr., R.L., Davies, B.J. (2009). Estimation of mortality and morbidity risk in patients undergoing radical cystectomy with continent diversion using the POSSUM and Portsmouth POSSUM predictor equations. J Urol,182(6): 2619-24. PubMed

Smaldone, M.C., Cowan, J., Carroll, P.R., Davies, B.J. (2010). Comparison of eligibility for active surveillance and pathologic outcomes in men undergoing radical prostatectomy in a large community-based cohort. J Urol,183(1):138-43. PubMed

Kutikov, A., Smaldone, M.C., Egleston, B.L., Manley, B.J., Simhan, J., Boorjian, S.A., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2011). Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephromety Score. Eur Urol, 60(2): 241-8. PubMed

Smaldone, M.C., Kutikov, A., Egleston, B., Simhan, J., Canter, D.J., Teper, E., Viterbo, R., Chen, D.Y., Greenberg, R.E., Uzzo, R.G. (2012). Assessing performance trends in laparoscopic nephrectomy and nephron sparing surgery for localized renal tumors. Urology, 80(2): 286-92. PubMed

Smaldone, M.C., Kutikov, A., Egleston, B.L., Canter, D.J., Viterbo, R., Chen, D.Y., Jewett, M.A., Greenberg, R.E., Uzzo, R.G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4):997-1006. PubMed

Smaldone, M.C., Egleston, B.L., Uzzo, R.G., Kutikov, A. (2012). Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol 188(6): 2089-94. PubMed... Expand

Additional Publications

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​